{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T19:20:27Z","timestamp":1793215227984,"version":"4.5.0"},"reference-count":112,"publisher":"MDPI AG","issue":"23","license":[{"start":{"date-parts":[[2021,11,27]],"date-time":"2021-11-27T00:00:00Z","timestamp":1637971200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Pseudomyxoma Peritonei (PMP) is an anatomo-clinical condition characterized by the implantation of neoplastic cells on peritoneal surfaces with the production of a large amount of mucin. The rarity of the disease precludes the evaluation of treatment strategies within randomized controlled trials. Cytoreductive Surgery (CRS) combined with Hyperthermic Intraperitoneal Chemotherapy (HIPEC) has proven to be the only therapeutic option with potential chances of cure and long-term disease control. The present review discusses the epidemiology, pathogenesis, clinical presentation and treatment of PMP, focusing on the molecular factors involved in tumor progression and mucin production that could be used, in the upcoming future, to improve patient selection for surgery and to expand the therapeutic armamentarium.<\/jats:p>","DOI":"10.3390\/cancers13235965","type":"journal-article","created":{"date-parts":[[2021,11,29]],"date-time":"2021-11-29T01:49:58Z","timestamp":1638150598000},"page":"5965","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Novel Perspectives in Pseudomyxoma Peritonei Treatment"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5764-5606","authenticated-orcid":false,"given":"Antonio","family":"Sommariva","sequence":"first","affiliation":[{"name":"Surgical Oncology of the Esophagus and Digestive Tract, Veneto Institute of Oncology IOV-IRCCS, 35100 Padua, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7190-2106","authenticated-orcid":false,"given":"Marco","family":"Tonello","sequence":"additional","affiliation":[{"name":"Surgical Oncology of the Esophagus and Digestive Tract, Veneto Institute of Oncology IOV-IRCCS, 35100 Padua, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Rigotto","sequence":"additional","affiliation":[{"name":"Immunology and Molecular Oncology, Veneto Institute of Oncology IOV-IRCCS, 35100 Padua, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nayana","family":"Lazzari","sequence":"additional","affiliation":[{"name":"Immunology and Molecular Oncology, Veneto Institute of Oncology IOV-IRCCS, 35100 Padua, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierluigi","family":"Pilati","sequence":"additional","affiliation":[{"name":"Surgical Oncology of the Esophagus and Digestive Tract, Veneto Institute of Oncology IOV-IRCCS, 35100 Padua, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9401-6182","authenticated-orcid":false,"given":"Maria Luisa","family":"Calabr\u00f2","sequence":"additional","affiliation":[{"name":"Immunology and Molecular Oncology, Veneto Institute of Oncology IOV-IRCCS, 35100 Padua, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,11,27]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1007\/BF01837425","article-title":"Klinische und anatomische Untersuchungen zur Lehre von den Bauchgeschw\u00fclsten und der Laparatomie","volume":"24","author":"Werth","year":"1884","journal-title":"Arch. Gyn\u00e4kol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1097\/01.sla.0000152015.76731.1f","article-title":"Long-term survival following treatment of pseudomyxoma peritonei: An analysis of surgical therapy","volume":"241","author":"Miner","year":"2005","journal-title":"Ann. Surg."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S1470-2045(05)70539-8","article-title":"New standard of care for appendiceal epithelial neoplasms and pseudomyxoma peritonei syndrome?","volume":"7","author":"Sugarbaker","year":"2006","journal-title":"Lancet Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e206363","DOI":"10.1001\/jamasurg.2020.6363","article-title":"The Role of Hyperthermic Intraperitoneal Chemotherapy in Pseudomyxoma Peritonei After Cytoreductive Surgery","volume":"156","author":"Kusamura","year":"2021","journal-title":"JAMA Surg."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1245\/s10434-009-0550-1","article-title":"Pseudomyxoma peritonei: A need to establish evidence-based standard of care--is this the right trial?","volume":"16","author":"Chua","year":"2009","journal-title":"Ann. Surg. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1097\/00000658-199502000-00002","article-title":"Prognostic features of 51 colorectal and 130 appendiceal cancer patients with peritoneal carcinomatosis treated by cytoreductive surgery and intraperitoneal chemotherapy","volume":"221","author":"Sugarbaker","year":"1995","journal-title":"Ann. Surg."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1097\/PPO.0b013e3181a58e74","article-title":"Technology of Hyperthermic Intraperitoneal Chemotherapy in the United States, Europe, China, Japan, and Korea","volume":"15","author":"Esquivel","year":"2009","journal-title":"Cancer J."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"e186847","DOI":"10.1001\/jamanetworkopen.2018.6847","article-title":"Morbidity and Mortality Rates Following Cytoreductive Surgery Combined With Hyperthermic Intraperitoneal Chemotherapy Compared With Other High-Risk Surgical Oncology Procedures","volume":"2","author":"Foster","year":"2019","journal-title":"JAMA Netw. Open"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1007\/s00432-009-0667-4","article-title":"Intraoperative hyperthermic intraperitoneal chemotherapy after cytoreductive surgery in ovarian cancer peritoneal carcinomatosis: Systematic review of current results","volume":"135","author":"Chua","year":"2009","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ejso.2020.02.012","article-title":"Appendiceal tumours and pseudomyxoma peritonei: Literature review with PSOGI\/EURACAN clinical practice guidelines for diagnosis and treatment","volume":"47","author":"Govaerts","year":"2021","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1097\/PAS.0000000000000535","article-title":"A Consensus for Classification and Pathologic Reporting of Pseudomyxoma Peritonei and Associated Appendiceal Neoplasia: The Results of the Peritoneal Surface Oncology Group International (PSOGI) Modified Delphi Process","volume":"40","author":"Carr","year":"2016","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_12","first-page":"122","article-title":"Adenocarcinoma of the appendix","volume":"Volume 3","author":"Bosman","year":"2010","journal-title":"WHO Classification of Tumours of the Digestive System"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1245\/s10434-017-6252-1","article-title":"Validation of the Recent PSOGI Pathological Classification of Pseudomyxoma Peritonei in a Single-Center Series of 265 Patients Treated by Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy","volume":"25","author":"Baratti","year":"2018","journal-title":"Ann. Surg. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1001\/jamasurg.2013.128","article-title":"Surgical quality measurement: An evolving science","volume":"148","author":"Merkow","year":"2013","journal-title":"JAMA Surg."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1002\/bjs.9641","article-title":"Publication of surgeon-specific outcomes","volume":"101","author":"Alderson","year":"2014","journal-title":"Br. J. Surg."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.soc.2018.02.009","article-title":"Learning Curve, Training Program, and Monitorization of Surgical Performance of Peritoneal Surface Malignancies Centers","volume":"27","author":"Kusamura","year":"2018","journal-title":"Surg Oncol Clin. N Am."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1002\/bjs.9674","article-title":"Multicentre study of the learning curve and surgical performance of cytoreductive surgery with intraperitoneal chemotherapy for pseudomyxoma peritonei","volume":"101","author":"Kusamura","year":"2014","journal-title":"Br. J. Surg."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"3831","DOI":"10.1245\/s10434-020-09312-w","article-title":"Management of Low-Grade Appendiceal Mucinous Neoplasms (LAMN): An International Survey of Surgeons Performing CRS and HIPEC","volume":"28","author":"Istl","year":"2021","journal-title":"Ann. Surg. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.ejso.2007.04.002","article-title":"Appendiceal neoplasms and pseudomyxoma peritonei: A population based study","volume":"34","author":"Smeenk","year":"2008","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1001\/jamasurg.2013.1212","article-title":"Increased risk of mucinous neoplasm of the appendix in adults undergoing interval appendectomy","volume":"148","author":"Furman","year":"2013","journal-title":"JAMA Surg."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1245\/s10434-017-6305-5","article-title":"Clinical Surveillance After Macroscopically Complete Surgery for Low-Grade Appendiceal Mucinous Neoplasms (LAMN) with or Without Limited Peritoneal Spread: Long-Term Results in a Prospective Series","volume":"25","author":"Guaglio","year":"2018","journal-title":"Ann. Surg. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1097\/PAS.0b013e3181af6067","article-title":"Appendiceal mucinous neoplasms: Clinicopathologic study of 116 cases with analysis of factors predicting recurrence","volume":"33","author":"Pai","year":"2009","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1097\/PAS.0b013e31817ec31e","article-title":"Prognostic significance of localized extra-appendiceal mucin deposition in appendiceal mucinous neoplasms","volume":"33","author":"Yantiss","year":"2009","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1186\/s12957-016-0996-0","article-title":"Early identification of DPAM in at-risk low-grade appendiceal mucinous neoplasm patients: A new approach to surveillance for peritoneal metastasis","volume":"14","author":"Foster","year":"2016","journal-title":"World J. Surg. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"5516","DOI":"10.1007\/s00464-019-07349-x","article-title":"Laparoscopic cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for perforated low-grade appendiceal mucinous neoplasms","volume":"34","author":"Abudeeb","year":"2020","journal-title":"Surg. Endosc."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1016\/j.ejso.2020.11.140","article-title":"Laparoscopic cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for limited peritoneal metastasis. The PSOGI international collaborative registry","volume":"47","author":"Aziz","year":"2021","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1016\/j.ejso.2012.07.009","article-title":"Outcome differences between debulking surgery and cytoreductive surgery in patients with Pseudomyxoma peritonei","volume":"38","author":"Andreasson","year":"2012","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.suronc.2019.03.004","article-title":"Survival after complete cytoreductive surgery and HIPEC for extensive pseudomyxoma peritonei","volume":"29","author":"Benhaim","year":"2019","journal-title":"Surg. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1080\/02656736.2020.1772511","article-title":"Complete pathologic response after two-stage cytoreductive surgery with HIPEC for bulky pseudomyxoma peritonei: Proof of concept","volume":"37","author":"Sgarbura","year":"2020","journal-title":"Int. J. Hyperth."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1245\/s10434-013-3213-1","article-title":"Intraperitoneal chemotherapy of peritoneal carcinomatosis using pressurized aerosol as an alternative to liquid solution: First evidence for efficacy","volume":"21","author":"Solass","year":"2014","journal-title":"Ann. Surg. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"e368","DOI":"10.1016\/S1470-2045(19)30318-3","article-title":"Pressurised intraperitoneal aerosol chemotherapy: Rationale, evidence, and potential indications","volume":"20","author":"Alyami","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.gore.2014.10.001","article-title":"Pressurized intraperitoneal aerosol chemotherapy (PIPAC) with cisplatin and doxorubicin in a woman with pseudomyxoma peritonei: A case report","volume":"10","author":"Tempfer","year":"2014","journal-title":"Gynecol. Oncol. Rep."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1186\/s12957-016-0892-7","article-title":"Safety and feasibility of pressurized intraperitoneal aerosol chemotherapy (PIPAC) associated with systemic chemotherapy: An innovative approach to treat peritoneal carcinomatosis","volume":"14","author":"Robella","year":"2016","journal-title":"World J. Surg. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1038\/s41430-020-00810-4","article-title":"Outcomes of home parenteral nutrition in 34 patients with intestinal failure from recurrent or progressive peritoneal malignancy of gastro-intestinal tract origin","volume":"75","author":"Swain","year":"2021","journal-title":"Eur. J. Clin. Nutr."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.gtc.2019.08.010","article-title":"Indications of Intestinal Transplantation","volume":"48","author":"Kahn","year":"2019","journal-title":"Gastroenterol. Clin. N. Am."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"S89","DOI":"10.1097\/01.tp.0000521415.60497.9b","article-title":"Extending the Indications of Intestinal Transplantation\u2014Modified multivisceral transplantation for end-stage pseudomyxoma peritoneii","volume":"101","author":"Reddy","year":"2017","journal-title":"Transplantation"},{"key":"ref_37","first-page":"BC04","article-title":"Cytoreductive surgery and multivisceral small bowel transplantation","volume":"3","author":"Cecil","year":"2018","journal-title":"Pleura Peritoneum"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1016\/j.ejso.2019.05.008","article-title":"Systemic chemotherapy before cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS\/HIPEC) in patients with high-grade mucinous carcinoma peritonei of appendiceal origin","volume":"45","author":"King","year":"2019","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1002\/cncr.29744","article-title":"The impact of stage, grade, and mucinous histology on the efficacy of systemic chemotherapy in adenocarcinomas of the appendix: Analysis of the National Cancer Data Base","volume":"122","author":"Asare","year":"2016","journal-title":"Cancer"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1002\/cncr.24715","article-title":"Modern systemic chemotherapy in surgically unresectable neoplasms of appendiceal origin: A single-institution experience","volume":"116","author":"Shapiro","year":"2010","journal-title":"Cancer"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/sj.bjc.6604522","article-title":"A phase II study evaluating the use of concurrent mitomycin C and capecitabine in patients with advanced unresectable pseudomyxoma peritonei","volume":"99","author":"Farquharson","year":"2008","journal-title":"Br. J. Cancer"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1093\/annonc\/mdw314","article-title":"Toward the molecular dissection of peritoneal pseudomyxoma","volume":"27","author":"Pietrantonio","year":"2016","journal-title":"Ann. Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"e179","DOI":"10.1016\/j.clcc.2019.03.002","article-title":"Metronomic Capecitabine With Cyclophosphamide Regimen in Unresectable or Relapsed Pseudomyxoma Peritonei","volume":"18","author":"Raimondi","year":"2019","journal-title":"Clin. Colorectal Cancer"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1007\/s10147-019-01592-x","article-title":"Efficacy of modified FOLFOX6 chemotherapy for patients with unresectable pseudomyxoma peritonei","volume":"25","author":"Hiraide","year":"2020","journal-title":"Int. J. Clin. Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1016\/S1470-2045(17)30422-9","article-title":"Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): An open-label, multicentre, phase 2 study","volume":"18","author":"Overman","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Andersson, Y., Fleten, K.G., Abrahamsen, T.W., Reed, W., Davidson, B., and Flatmark, K. (2021). Anti-Angiogenic Treatment in Pseudomyxoma Peritonei-Still a Strong Preclinical Rationale. Cancers, 13.","DOI":"10.3390\/cancers13112819"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1016\/j.ajpath.2014.03.004","article-title":"Orthotopic animal model of pseudomyxoma peritonei: An in vivo model to test anti-angiogenic drug effects","volume":"184","author":"Dohan","year":"2014","journal-title":"Am. J. Pathol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1245\/s10434-014-4335-9","article-title":"Improved Survival with Anti-VEGF Therapy in the Treatment of Unresectable Appendiceal Epithelial Neoplasms","volume":"22","author":"Choe","year":"2015","journal-title":"Ann. Surg. Oncol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"29","DOI":"10.21037\/cco-21-2","article-title":"A case of pseudomyxoma peritonei successfully treated with trifluridine\/tipiracil (TAS-102) and bevacizumab after palliative debulking surgery","volume":"10","author":"Hirano","year":"2021","journal-title":"Chin. Clin. Oncol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1186\/s12967-016-0877-x","article-title":"GNAS mutations as prognostic biomarker in patients with relapsed peritoneal pseudomyxoma receiving metronomic capecitabine and bevacizumab: A clinical and translational study","volume":"14","author":"Pietrantonio","year":"2016","journal-title":"J. Transl. Med."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"22067","DOI":"10.1200\/jco.2008.26.15_suppl.22067","article-title":"Analysis of immunohistochemical predictors of outcome in pseudomyxoma peritonei","volume":"26","author":"Foster","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.jss.2012.10.053","article-title":"Kras mutations and p53 overexpression in pseudomyxoma peritonei: Association with phenotype and prognosis","volume":"180","author":"Shetty","year":"2013","journal-title":"J. Surg. Res."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.humpath.2019.12.008","article-title":"Pathological prognostic factors of pseudomyxoma peritonei: Comprehensive clinicopathological analysis of 155 cases","volume":"97","author":"Yan","year":"2020","journal-title":"Hum. Pathol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"3000605211022297","DOI":"10.1177\/03000605211022297","article-title":"Prognostic significance of CEA, Ki67 and p53 in pseudomyxoma peritonei of appendiceal origin","volume":"49","author":"Yan","year":"2021","journal-title":"J. Int. Med. Res."},{"key":"ref_55","unstructured":"Arjona-Sanchez, A., Martinez-Lopez, A., Valenzuela-Molina, F., Rufian-Andujar, B., Rufian-Pena, S., Casado-Adam, A., Sanchez-Hidalgo, J.M., Rodriguez-Ortiz, L., Medina-Fernandez, F.J., and Diaz-Lopez, C. (2021). A Proposal for Modification of the PSOGI Classification According to the Ki-67 Proliferation Index in Pseudomyxoma Peritonei. Ann. Surg. Oncol."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Kuracha, M.R., Thomas, P., Loggie, B.W., and Govindarajan, V. (2017). Bilateral blockade of MEK- and PI3K-mediated pathways downstream of mutant KRAS as a treatment approach for peritoneal mucinous malignancies. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0179510"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1007\/s00432-020-03321-8","article-title":"The biological basis and function of GNAS mutation in pseudomyxoma peritonei: A review","volume":"146","author":"Lin","year":"2020","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1159\/000477562","article-title":"Clinical Benefit from Trametinib in a Patient with Appendiceal Adenocarcinoma with a GNAS R201H Mutation","volume":"10","author":"Ang","year":"2017","journal-title":"Case Rep. Oncol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1038\/modpathol.2014.37","article-title":"Clinicopathologic and molecular analysis of disseminated appendiceal mucinous neoplasms: Identification of factors predicting survival and proposed criteria for a three-tiered assessment of tumor grade","volume":"27","author":"Davison","year":"2014","journal-title":"Mod. Pathol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1158\/1078-0432.CCR-11-2381","article-title":"The clinical effect of the dual-targeting strategy involving PI3K\/AKT\/mTOR and RAS\/MEK\/ERK pathways in patients with advanced cancer","volume":"18","author":"Shimizu","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"22976","DOI":"10.3390\/ijms160922976","article-title":"Dual Inhibition of MEK and PI3K Pathway in KRAS and BRAF Mutated Colorectal Cancers","volume":"16","author":"Temraz","year":"2015","journal-title":"Int. J. Mol. Sci."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/s41586-019-1694-1","article-title":"The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity","volume":"575","author":"Canon","year":"2019","journal-title":"Nature"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1158\/2159-8290.CD-19-1167","article-title":"The KRAS(G12C) Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients","volume":"10","author":"Hallin","year":"2020","journal-title":"Cancer Discov."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"10786","DOI":"10.18632\/oncotarget.3198","article-title":"Global gene expression in pseudomyxoma peritonei, with parallel development of two immortalized cell lines","volume":"6","author":"Roberts","year":"2015","journal-title":"Oncotarget"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.jamcollsurg.2011.12.028","article-title":"Gene expression profiling of peritoneal metastases from appendiceal and colon cancer demonstrates unique biologic signatures and predicts patient outcomes","volume":"214","author":"Levine","year":"2012","journal-title":"J. Am. Coll. Surg."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.jamcollsurg.2015.12.012","article-title":"Prognostic Molecular Subtypes of Low-Grade Cancer of the Appendix","volume":"222","author":"Levine","year":"2016","journal-title":"J. Am. Coll. Surg."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1097\/COC.0000000000000376","article-title":"Appendix-derived Pseudomyxoma Peritonei (PMP): Molecular Profiling Toward Treatment of a Rare Malignancy","volume":"41","author":"Gleeson","year":"2018","journal-title":"Am. J. Clin. Oncol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"3096","DOI":"10.1158\/1078-0432.CCR-18-3388","article-title":"Molecular Profiling of Appendiceal Adenocarcinoma and Comparison with Right-sided and Left-sided Colorectal Cancer","volume":"25","author":"Tokunaga","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"164","DOI":"10.21037\/jgo.2017.01.14","article-title":"Potential actionable targets in appendiceal cancer detected by immunohistochemistry, fluorescent in situ hybridization, and mutational analysis","volume":"8","author":"Borazanci","year":"2017","journal-title":"J. Gastrointest. Oncol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1038\/nrc2761","article-title":"Mucins in cancer: Function, prognosis and therapy","volume":"9","author":"Kufe","year":"2009","journal-title":"Nat. Rev. Cancer"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.critrevonc.2017.12.006","article-title":"Mucins: Structural diversity, biosynthesis, its role in pathogenesis and as possible therapeutic targets","volume":"122","author":"Dhanisha","year":"2018","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"18","DOI":"10.7150\/ijms.16422","article-title":"Physical and chemical characteristics of mucin secreted by pseudomyxoma peritonei (PMP)","volume":"14","author":"Pillai","year":"2017","journal-title":"Int. J. Med. Sci."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1002\/ijc.28380","article-title":"A formulation for in situ lysis of mucin secreted in pseudomyxoma peritonei","volume":"134","author":"Pillai","year":"2014","journal-title":"Int. J. Cancer"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"33329","DOI":"10.18632\/oncotarget.5259","article-title":"Depletion of mucin in mucin-producing human gastrointestinal carcinoma: Results from in vitro and in vivo studies with bromelain and N-acetylcysteine","volume":"6","author":"Amini","year":"2015","journal-title":"Oncotarget"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"4117","DOI":"10.1016\/j.bbagen.2013.04.016","article-title":"The chemistry and biological activities of N-acetylcysteine","volume":"1830","author":"Samuni","year":"2013","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"976203","DOI":"10.1155\/2012\/976203","article-title":"Properties and therapeutic application of bromelain: A review","volume":"2012","author":"Pavan","year":"2012","journal-title":"Biotechnol. Res. Int."},{"key":"ref_77","unstructured":"Valle, S.J., Akhter, J., Mekkawy, A.H., Lodh, S., Pillai, K., Badar, S., Glenn, D., Power, M., Liauw, W., and Morris, D.L. (2019). A novel treatment of bromelain and acetylcysteine (BromAc) in patients with peritoneal mucinous tumours: A phase I first in man study. Eur. J. Surg. Oncol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1006\/geno.1996.0637","article-title":"Human mucin genes assigned to 11p15.5: Identification and organization of a cluster of genes","volume":"38","author":"Pigny","year":"1996","journal-title":"Genomics"},{"key":"ref_79","first-page":"675","article-title":"Sequence of the 5\u2032-flanking region and promoter activity of the human mucin gene MUC5B in different phenotypes of colon cancer cells","volume":"348 Pt. 3","author":"Perrais","year":"2000","journal-title":"Biochem. J."},{"key":"ref_80","first-page":"D1216","article-title":"Transcriptional regulation of the 11p15 mucin genes. Towards new biological tools in human therapy, in inflammatory diseases and cancer?","volume":"6","author":"Pigny","year":"2001","journal-title":"Front. Biosci."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"6566","DOI":"10.1038\/sj.onc.1210479","article-title":"Epigenetic regulation (DNA methylation, histone modifications) of the 11p15 mucin genes (MUC2, MUC5AC, MUC5B, MUC6) in epithelial cancer cells","volume":"26","author":"Vincent","year":"2007","journal-title":"Oncogene"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"5718","DOI":"10.1073\/pnas.95.10.5718","article-title":"Activation of NF-kappaB via a Src-dependent Ras-MAPK-pp90rsk pathway is required for Pseudomonas aeruginosa-induced mucin overproduction in epithelial cells","volume":"95","author":"Li","year":"1998","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.trsl.2012.08.001","article-title":"Hypoxia induces mucin expression and secretion in human bronchial epithelial cells","volume":"160","author":"Zhou","year":"2012","journal-title":"Transl. Res."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.trsl.2015.03.004","article-title":"Mitogen-activated protein kinase inhibition reduces mucin 2 production and mucinous tumor growth","volume":"166","author":"Dilly","year":"2015","journal-title":"Transl. Res."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"32258","DOI":"10.1074\/jbc.M204862200","article-title":"Induction of MUC2 and MUC5AC mucins by factors of the epidermal growth factor (EGF) family is mediated by EGF receptor\/Ras\/Raf\/extracellular signal-regulated kinase cascade and Sp1","volume":"277","author":"Perrais","year":"2002","journal-title":"J. Biol. Chem."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/gm559","article-title":"Genome-wide mutational landscape of mucinous carcinomatosis peritonei of appendiceal origin","volume":"6","author":"Alakus","year":"2014","journal-title":"Genome Med."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1245\/s10434-012-2242-5","article-title":"Chronic anti-inflammatory drug therapy inhibits gel-forming mucin production in a murine xenograft model of human pseudomyxoma peritonei","volume":"19","author":"Choudry","year":"2012","journal-title":"Ann. Surg. Oncol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1756-8722-3-8","article-title":"From basic research to clinical development of MEK1\/2 inhibitors for cancer therapy","volume":"3","author":"Fremin","year":"2010","journal-title":"J. Hematol. Oncol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1038\/sj.bjc.6603398","article-title":"A specific cadherin phenotype may characterise the disseminating yet non-metastatic behaviour of pseudomyxoma peritonei","volume":"95","author":"Bibi","year":"2006","journal-title":"Br. J. Cancer"},{"key":"ref_90","doi-asserted-by":"crossref","unstructured":"Chakraborty, S., Kubatzky, K.F., and Mitra, D.K. (2019). An Update on Interleukin-9: From Its Cellular Source and Signal Transduction to Its Role in Immunopathogenesis. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20092113"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"a028449","DOI":"10.1101\/cshperspect.a028449","article-title":"The Common Cytokine Receptor gamma Chain Family of Cytokines","volume":"10","author":"Lin","year":"2018","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.3109\/10428194.2012.745072","article-title":"The role of interleukin-9 in lymphoma","volume":"54","author":"Lv","year":"2013","journal-title":"Leuk. Lymphoma"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"2831056","DOI":"10.1155\/2017\/2831056","article-title":"Interleukin-9 Promotes Pancreatic Cancer Cells Proliferation and Migration via the miR-200a\/Beta-Catenin Axis","volume":"2017","author":"Hu","year":"2017","journal-title":"Biomed. Res. Int."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"299","DOI":"10.3892\/ol.2020.11570","article-title":"miR-208b-5p inhibits invasion of non-small cell lung cancer through the STAT3 pathway by targeting interleukin-9","volume":"20","author":"Ma","year":"2020","journal-title":"Oncol. Lett."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1136\/gutjnl-2013-305947","article-title":"IL-9 and its receptor are predominantly involved in the pathogenesis of UC","volume":"64","author":"Nalleweg","year":"2015","journal-title":"Gut"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"6006","DOI":"10.1158\/1078-0432.CCR-13-1130","article-title":"Proteome profiling of cancer-associated fibroblasts identifies novel proinflammatory signatures and prognostic markers for colorectal cancer","volume":"19","author":"Torres","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"ref_97","first-page":"2384","article-title":"Targeting the JAK\/STAT pathway in solid tumors","volume":"6","author":"Qureshy","year":"2020","journal-title":"J. Cancer Metastasis Treat."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/nrc1361","article-title":"The proteasome: A suitable antineoplastic target","volume":"4","author":"Adams","year":"2004","journal-title":"Nat. Rev. Cancer"},{"key":"ref_99","first-page":"996","article-title":"Analysis of the efficacy and toxicity of bortezomib for treatment of relapsed or refractory multiple myeloma in community practice","volume":"90","author":"Wu","year":"2005","journal-title":"Haematologica"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1038\/leu.2010.129","article-title":"Primary therapy with single agent bortezomib as induction, maintenance and re-induction in patients with high-risk myeloma: Results of the ECOG E2A02 trial","volume":"24","author":"Dispenzieri","year":"2010","journal-title":"Leukemia"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.ygyno.2009.07.023","article-title":"A phase II evaluation of bortezomib in the treatment of recurrent platinum-sensitive ovarian or primary peritoneal cancer: A Gynecologic Oncology Group study","volume":"115","author":"Aghajanian","year":"2009","journal-title":"Gynecol. Oncol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1158\/1541-7786.MCR-15-0237","article-title":"Hypoxia Promotes Synergy between Mitomycin C and Bortezomib through a Coordinated Process of Bcl-xL Phosphorylation and Mitochondrial Translocation of p53","volume":"13","author":"Song","year":"2015","journal-title":"Mol. Cancer Res."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1039\/C3MD00386H","article-title":"Identification of an inhibitor of the ubiquitin\u2013proteasome system that induces accumulation of polyubiquitinated proteins in the absence of blocking of proteasome function","volume":"5","author":"Haglund","year":"2014","journal-title":"MedChemComm"},{"key":"ref_104","first-page":"1771","article-title":"Functions of EpCAM in physiological processes and diseases (Review)","volume":"42","author":"Huang","year":"2018","journal-title":"Int. J. Mol. Med."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/sj.bjc.6602924","article-title":"Frequent high-level expression of the immunotherapeutic target Ep-CAM in colon, stomach, prostate and lung cancers","volume":"94","author":"Went","year":"2006","journal-title":"Br. J. Cancer"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1002\/1097-0215(20001215)88:6<970::AID-IJC21>3.0.CO;2-Q","article-title":"Systemic immunotoxin treatment inhibits formation of human breast cancer metastasis and tumor growth in nude rats","volume":"88","author":"Engebraaten","year":"2000","journal-title":"Int. J. Cancer"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1038\/sj.bjc.6605312","article-title":"Synergistic anti-cancer effects of immunotoxin and cyclosporin in vitro and in vivo","volume":"101","author":"Andersson","year":"2009","journal-title":"Br. J. Cancer"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.3390\/toxins5081486","article-title":"Immunotoxins: The role of the toxin","volume":"5","author":"Antignani","year":"2013","journal-title":"Toxins"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1002\/ijc.28158","article-title":"Immunotoxin targeting EpCAM effectively inhibits peritoneal tumor growth in experimental models of mucinous peritoneal surface malignancies","volume":"133","author":"Flatmark","year":"2013","journal-title":"Int. J. Cancer"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1245\/s10434-017-5814-6","article-title":"Novel Treatment with Intraperitoneal MOC31PE Immunotoxin in Colorectal Peritoneal Metastasis: Results From the ImmunoPeCa Phase 1 Trial","volume":"24","author":"Froysnes","year":"2017","journal-title":"Ann. Surg. Oncol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"5252","DOI":"10.1245\/s10434-021-10022-0","article-title":"Increased Local Inflammatory Response to MOC31PE Immunotoxin After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy","volume":"28","author":"Thorgersen","year":"2021","journal-title":"Ann. Surg. Oncol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.ejso.2019.04.014","article-title":"ImmunoPeCa trial: Long-term outcome following intraperitoneal MOC31PE immunotoxin treatment in colorectal peritoneal metastasis","volume":"47","author":"Froysnes","year":"2021","journal-title":"Eur. J. Surg. Oncol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/13\/23\/5965\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:36:34Z","timestamp":1760168194000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/13\/23\/5965"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,27]]},"references-count":112,"journal-issue":{"issue":"23","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["cancers13235965"],"URL":"https:\/\/doi.org\/10.3390\/cancers13235965","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,27]]}}}